GLP1R and rheumatoid arthritis: Treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, −0.34 percentage points; 95% CI, −0.44 to −0.24 percentage points) and body weight (treatment difference, −2.9 kg, 95% CI, −4.8 to −1.1 kg) compared with GLP-1 RA.